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Abstract: G-protein-coupled receptors associate into dimers/oligomers whose function is not well 
understood. One approach to investigate this issue is to challenge oligomerization by peptides 
replicating transmembrane domains and to study their effect on receptor functionality. The 
disruptor peptides are typically delivered by means of cell-penetrating vectors such as the human 
immunodeficiency virus (HIV) transcription trans-activation protein Tat. In this paper we report a 
cyclic, Tat-like peptide that significantly improves its linear analogue in targeting interreceptor 
sequences in the transmembrane space. The same cyclic Tat-like vector fused to a transmembrane 
region not involved in receptor oligomerization was totally ineffective. Besides higher efficacy, the 
cyclic version has enhanced proteolytic stability, as shown by trypsin digestion experiments. 




G-protein-coupled receptors (GPCRs), the most populated gene family in the human genome, 
are cell-surface receptors also known as heptaspanning receptors because they contain seven 
transmembrane (TM) alpha-helical domains. The widely used Kolakowski system groups GPCRs 
into six classes (A to F), with subclasses annotated using Roman numerals [1,2]. In addition to the 
seven TM helices, GPCRs also have intracellular C-terminal and extracellular N-terminal domains of 
variable length. Class C GCPRs (e.g., taste, glutamate or -aminobutyric acid receptors) are able to 
form a variety of homo and heteromers (reported as dimers or tetramers) when expressed in 
heterologous systems. These assemblies are consistent with 3D structural data showing that 
extracellular domains arrange into dimers [3–8]. Class A (rhodopsin-like) receptors, the most 
abundant GPCR group, was assumed for years to act as monomers, but this view has radically 
changed as many class A GPCRs are expressed as homo- and/or heteroreceptor complexes [9], and 
there is even in vivo evidence obtained by functional rescue using defective mutants of the 
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gonadotropin releasing hormone receptor [10]. There are already several 3D structures for class A 
receptors and in many of the crystals the packing of molecules could fit with dimer formation in a 
biological membrane [11]. Recently the first 3D structure of a dimer of a full-length class C receptor, 
i.e., also containing the seven TM helical domains, has been reported for both inactive and active 
states [12]; this fact raises hopes for similar data coming soon for dimers of class A receptors. 
One of the challenges in GPCR homo and heteromer research is to characterize the specific 
properties of the complexes, including differential functionality, if any. While potent tools exist to 
detect GPCR complex formation [9,13,14], the assessment of their functionality is, by far, more 
problematic. We have successfully shown, using chimeric peptide constructs, how disruption of 
homo/heteromer structure alters agonist-induced functionality and provides knowledge on the 
physiological role of GPCR receptor–receptor interactions. The most used peptide chimeras consist 
of the cell-penetrating peptide (CPP) sequence of the human immunodeficiency virus (HIV-1) trans-
activation of transcription (Tat) protein, fused to a suitably chosen TM domain of the GPCR. Insertion 
into the membrane lipid bilayer and placement of such Tat-TM chimeras within the interaction 
interface alters the overall quaternary structure and can in turn assess the loss of function brought 
about by peptide-driven homo/heteromer disruption [15,16]. We have previously used this approach 
to decipher the structure and function of the complex formed by two class A adenosine GCPRs 
[17,18], and for other (adenosine-receptor-unrelated) heteroreceptor complexes [19,20]. 
As they crisscross from extracellular to intracellular space, TM helical domains adopt alternating 
orientations (i.e., N- to C-terminal in TM1, TM3, TM5 and TM7, C- to N-terminal in TM2, TM4 and 
TM6). This fact must be accounted for in the design of Tat-TM chimeras, to ensure that their insertion 
into cell membranes reproduces the native alignment. For instance, an interfering peptide based on 
the TM3 helix needs to be synthesized with the CPP moiety at the C-terminus, so that upon insertion 
the N-terminus of TM3 sequence will end up close to the extracellular space, and so on [21]. 
Despite the potential of the Tat-TM approach to modulate GPCR complex formation, experience 
indicates that the quantitative effect of linear Tat-TM constructs is limited. This can be attributed to 
transient, unproductive interactions causing “dilution” of the TM moiety within the membrane, but 
it also stems from the intrinsic lability of the Tat sequence, rich in basic (Arg, Lys) residues and, 
therefore, susceptible to the action of trypsin-like proteases or convertases [22,23]. Proteolytic 
degradation, a major hurdle in peptide therapeutic development, can be circumvented or at least 
mitigated in various ways; for instance, cyclization can protect the N- and/or C-termini from the 
action of exoproteases [24]. This strategy underlies some recent accounts of cyclic, Tat-inspired CPPs 
[25]. In tune with these findings, here we aim to compare the relative efficacy of cyclic vs. linear Tat-
based CPPs in interfering with GCPR heteromer formation and function. We also show how our 
approach, where cyclization is combined with d-amino acid modification, also bears favorably upon 
resistance to proteolytic cleavage of the cyclic CPP construction. 
2. Results and Discussion 
2.1. Peptide Design and Synthesis 
This study uses two fully linear sequences (Table 1, entries 1 and 3) and two peptides (entries 2 
and 4) where the TM5 and TM7 helical domains of A2AR are fused to a cyclic motif (Figure 1). Of the 
two TM domains, TM5 is a putative GPCR homodimer disruptor, whereas TM7 is not present in 
homodimer interfaces and, thus, often used as a negative control [17,18]. In peptides 2 and 4, the 
cyclic moiety is generated by an intramolecular (amide bond) cyclization between the side chains of 
the N-terminal Lys (K) and C-terminal Glu (E) residues of the KrRrGrKkRrE sequence, inspired on 
the Tat(47−57) CPP sequence (YGRKKRRQRRR), and containing alternating L- and D- residues. All 
four peptides were efficiently obtained by state-of-the-art Fmoc solid-phase synthesis, with careful 
monitoring of the selective deprotection and cyclization steps of 2 and 4 (see Section 3.1 below). 
Further details are given in Table 1. 
Table 1. Peptides used in this study. 
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Peptide Description Sequence MW, Da 
1 Linear Tat-based TM5 MNYMVYFNFFACVLVPLLLMLGVYLYGRKKRRQRRR-amide 4514.60 
2 Cyclic Tat-like TM5 a MNYMVYFNFFACVLVPLLLMLGVYL[KrRrGrKkRrE]-amide 4504.60 
3 Linear Tat-based TM7 LWLMYLAIVLSHTNSVVNPFIYAYYGRKKRRQRRR-amide 4369.22 
4 Cyclic Tat-like TM7 a LWLMYLAIVLSHTNSVVNPFIYAY[KrRrGrKkRrE]-amide 4359.22 
a The sequence within brackets denotes intramolecular, amide bond cyclization between the Lys (K) and the C-
terminal Glu (E) residues; N-terminus is acetylated. 
 
Figure 1. Structure of cyclic Tat-like construct KrRrGrKkRrE fused to A2AR transmembrane (TM)-
interfering sequences. The amide bond between the ε–amino group of the N-terminal Lys and the γ–
carboxyl of C-terminal Glu is marked with an asterisk. 
2.2. Effect of Transmembrane (TM)-Cyclic Cell-Penetrating Peptides (CPPs) as Disruptors of A2A Receptor 
Dimerization 
An heterologous system consisting of HEK-293T cells was used to express the adenosine A2A 
receptor, which in these cells is able to form homodimers [26], as confirmed by bioluminescence 
resonance energy transfer (BRET) using cells transfected with cDNA for A2ARluc (0.2 µg), increasing 
amounts of cDNA coding for A2AR-yellow fluorescent protein, and addition of the Renilla luciferase 
(Rluc) substrate, coelenterazine H. The saturable BRET curve displayed in Figure 2A proves 
molecular interaction between two molecules of the A2AR. These results on receptor 
homodimerization confirm those reported elsewhere [26]. 
For bimolecular fluorescence complementation (BiFC) assays, cells were transfected using 
cDNAs coding for two versions of the receptor. As described elsewhere [18,27], two cDNAs were 
prepared: each encoding the receptor fused to one of the two halves of the super yellow fluorescent 
protein (sYFP). 48 h post-transfection the fluorescence was determined in the absence and in the 
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presence of linear peptides 1 and 3 or the corresponding cyclic peptides 2 and 4 after 4 h incubation. 
Each half of the fluorescent protein is unable, by itself, to emit fluorescence, which is only feasible 
after complementation of the two halves of the sYFP. If the peptide affects the structure of the dimer, 
the proteins are separated (to a greater or lesser extent) and fluorescence is reduced or lost. A 
comparison of the effect of the peptides on the “control” fluorescence, that is, the fluorescence given 
by the dimer in the absence of peptides is shown in Figure 2B. 
TM7-displaying constructions, either linear (3) or cyclic (4), did not significantly affect the 
fluorescence of the control, thus confirming that TM7 does not participate in the dimerization (not 
shown). In contrast, both TM5-bearing peptides 1 and 2 affected the fluorescence of the control in a 
dose-response manner (Figure 2B). Interestingly, while the experiment shows linear peptide 1 
perturbing A2AR dimerization, the cyclic version 2 produced a more marked, statistically significant, 
effect than its linear counterpart. IC50 values were 0.52 µM and 0.35 µM for, respectively, the linear 
and the cycle-bearing molecules. 
How linear and cyclic TM5 peptides affect signaling was addressed by determining cytosolic 
cyclic adenylic acid (cAMP) levels. As the A2A receptor is coupled to Gs, its activation leads to 
increased cytosolic cAMP concentration. Both peptides significantly reduced the agonist (CGS-
21680)-induced effect although with no statistical significance between data from linear and cyclic 
peptide (Figure 2). A control using the selective antagonist SCH-58621 blocked cAMP production 
under all conditions. The reduction in Gs-mediated signaling is moderate, in contrast with results 
with interfering (linear) peptides altering the quaternary structure and, subsequently, the signaling 
properties of GPCR heteromers. This difference may be explained by assuming two different GPCRs 
arranging into a heteromer made of two homodimers (stoichiometry 2:2) that can accommodate two 
different G proteins [17,18]. In this quaternary arrangement, interfering peptides for homodimers 
may be able to affect G coupling but only mildly, whereas the potency of interfering peptides for 
heteromers may be higher as they affect allosteric interactions occurring between the two different G 
proteins when the receptors are activated. In our experience, interfering peptides interacting with 
heteromeric interfaces have always been able to markedly alter the properties of the GPCR heteromer. 
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Figure 2. Bioluminescence resonance energy transfer (BRET) assays for homodimer receptor 
identification and bimolecular fluorescence complementation and signaling in cells expressing A2A 
receptors in the presence of linear and cyclic Tat-like (disrupting) peptides 1 (linear TM5-Tat) and 2 
(TM5-cyclic Tat-like). A scheme of BRET (A), molecular complementation (B) and cAMP 
determination (C) assays is shown close to each graph; AC = adenylyl cyclase. Panel A: data are mean 
+/− standard deviation (SD, n = 6 in duplicates). The blue arrow in the upper illustration denotes that, 
only if dimerization occurs, energy transfer from RLuc to coelenterazine H takes place, causing YFP 
excitation hence fluorescence emission. Panel B: data are mean +/− SD (n = 12 in duplicates); *** p < 
0.001 respect to each control (analysis of variance (ANOVA) followed by Bonferroni’s post-hoc tests). 
Panel C: data are the mean (in % of increase over basal) +/- SD (n = 8 in duplicates). * p < 0.05 with 
respect to absence of peptides and no significant differences in linear versus cyclic by two-factor 
ANOVA analysis. 
2.3. Peptide Susceptibility to Trypsin 
It was of particular interest to ascertain how the internal cyclization and D-amino acid 
modifications influenced the lifespan of the partially cyclic structures. To this end, peptides 1 and 2, 
both with a TM5 disruptor sequence fused to a linear or a cyclic CPP motif, respectively, were 
inspected by high-performance liquid chromatography (HPLC) upon trypsin treatment. Analysis 
confirmed the vulnerability of fully linear 1 (Figure 3), with a 90% decrease in the area of the starting 
peak after only 30 min (Figure 4), and the appearance of new peaks identified by mass spectrometry 
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(MS) (Table 2). In sharp contrast, cyclic analog 2 proved highly impervious to digestion, with over 
50% of the starting peptide unaltered after 24 h (Figure 4). 
 
Figure 3. High-performance liquid chromatography (HPLC) analysis of fully linear peptide 1 on 
incubation with trypsin over 30 min. Starting material corresponds to peak 1 (black trace). Main 
tryptic fragments (2−8) are identified by mass on Table 2. 
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3 7.76 MNYMVYFNFFACVLVPLLLMLGVYLYGRKKRRQR-carboxyl 4203.20 4202.40 
4 8.24 MNYMVYFNFFACVLVPLLLMLGVYLYGRKKRR-carboxyl 3918.89 3919.05 
5 8.81 MNYMVYFNFFACVLVPLLLMLGVYLYGRKKR-carboxyl 3762.70 3763.35 
6 9.57 MNYMVYFNFFACVLVPLLLMLGVYLYGRKK-carboxyl 3606.51 3606.45 
7 10.90 MNYMVYFNFFACVLVPLLLMLGVYLYGRK-carboxyl 3478.34 3477.75 
8 12.62 MNYMVYFNFFACVLVPLLLMLGVYLYGR-carboxyl 3350.16 3351.60 
a Peptides were analyzed by HPLC with a 40%−90% linear gradient of acetonitrile over 15 min. Identity was established by HPLC-mass spectrometry (MS) (details 
in Materials and Methods); b Residues in red correspond to the cell-penetrating sequence.
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Figure 4. HPLC analysis of cyclic cell-penetrating peptides (CPP)-containing peptide 2 upon 
incubation with trypsin after 24 h. Inset: comparison of linear (1) and cyclic (2) peptide survival. Area 
of starting peak remaining at the stated time points is shown. Assays were done in duplicate. 
GraphPad prism was used to fit data. 
3. Materials and Methods  
3.1. Peptides 
The sequences on Table 1 were assembled on 50 µmol (0.106 g; 0.47 mmol/g) of Fmoc-Rink-
amide ChemMatrix resin in a Prelude instrument (Gyros Protein Technologies, Tucson, AZ) running 
optimized Fmoc synthesis protocols. Couplings with a 5-fold excess of Fmoc-amino acid, in the 
presence of 2-(1H-benzotriazol-1-yl)-1,1,3,3 tetramethyluronium hexafluorophosphate (HBTU, 5-fold 
excess) and N,N-diisopropylethylamine (DIEA, 10-fold excess), with N,N- dimethylformamide (DMF) 
as solvent for 5 + 5 min, were systematically repeated for all residues. Fmoc removal was done with 
20% (v/v) piperidine in DMF for 2 × 2.5 min. Coupling and deprotection steps were separated by DMF 
washes (6 × 30 sec). For the two fully linear sequences (Table 1), side chain protections were Boc (Lys, 
Trp), 2,2,4,6,7 pentamethyldihydrobenzofuran-5-sulfonyl (Arg), t-butyl (Glu, Ser, Thr, Tyr) and trityl 
(Asn, Cys, Gln, His).  
For sequences 2 and 4 containing the cyclic CPP motif (Figure 1), the Lys and Glu residues 
involved in intramolecular cyclization (Table 1) were orthogonally protected with (4-
methoxyphenyl)diphenylmethyl (Mmt) and 2-phenyisopropyl (O-2-PhiPr) groups, respectively. In 
those syntheses, the C-terminal Fmoc-Glu (O-2-PhiPr)-OH (97.5 mg, 200 µmol) was loaded manually 
in the presence of HBTU (75.8 mg, 200 µmol) and DIEA (70 µL, 400 µmol), 1 h in DMF (double 
coupling). At the end of these two syntheses, the Fmoc group was removed and the N-terminal was 
capped by acetylation with acetic anhydride (37.81 µL, 400 µmol) and DIEA (140 µL, 800 µmol) in 
DMF for 1 h. After assembly, the peptide resins were treated with 1% (v/v) trifluoroacetic acid (TFA) 
in CH2Cl2 (4 × 10 min) for simultaneous orthogonal removal of O-2-PhiPr and Mmt groups, followed 
by neutralization with 5% DIEA in CH2Cl2 (4 × 5 min). Cyclization was next done with 
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PyBOP/HOBt/DIPEA (5, 5, and 10 equiv) in DMF for 3 h, when a negative ninhydrin test was 
observed. A mini-cleavage with ~5 mg resin was also performed to check the purity and identity of 
the resin-bound product after the cyclization step. 
Finally, all peptide-resins were treated with TFA/H2O/DODT/triisopropylsilane (94:2.5:2.5:1 v/v, 
90 min) for full deprotection and cleavage. Peptides were isolated by precipitation with chilled 
diethyl ether, centrifuged for 3 × 10 min at 4 °C, taken up in H2O and lyophilized. 
3.2. Peptide Analysis and Purification 
Reconstitution of the lyophilized peptides was usually straightforward (H2O, acidified with 
HOAc if necessary). The crude peptides were analyzed by HPLC on Luna C18 columns (4.6 × 50 mm, 
3 µm, Phenomenex, Torrance, CA, USA) in a LC-20AD system (Shimadzu, Kyoto, Japan). Elution was 
with linear gradients of solvent B (0.036% v/v TFA in CH3CN) into A (0.045% v/v TFA in H2O) over 
15 min. Peptides were purified by preparative HPLC on Luna C18 columns (10 × 250 mm, 10 µm, 
Phenomenex) in a Shimadzu LC-8A instrument using linear gradients of solvent B (0.1% v/v TFA in 
CH3CN) into A (0.1% v/v TFA in H2O) over 30 min, at 7 mL/min flow rate with UV detection at 220 
nm. Fractions of satisfactory purity (>95%) by analytical HPLC were pooled, lyophilized and 
analyzed for identity by HPLC-MS (C18 column, 4.6 × 150 mm, 3.5 µm, Phenomenex, Torrance, CA, 
USA) in a Shimadzu LC-MS 2010EV instrument, eluting with linear gradients of solvent B (0.08% v/v 
HCOOH in CH3CN) into A (0.1% v/v TFA in H2O) over 15 min at 1 mL/min flow rate. 
3.3. Trypsin Digestion 
A 1000 µg/1000 µL trypsin solution (Thermo Fisher Scientific, Cornellà de Llobregat, Spain) city, 
state abbreviation if available, country) was prepared by suspending the lyophilized enzyme in 50 
mM ammonium bicarbonate buffer, pH 8.2. Peptides dissolved in the same buffer (1 µg/µL) were 
incubated with trypsin (peptide:trypsin ratio = 100:1) for 24 h at 37 °C. Samples were collected at 
various time points and digestion was stopped by addition of 20% (v/v) of 0.5% formic acid in H2O. 
Samples were stored at −20 °C until analyzed by reverse-phase HPLC-MS. 
3.4. Bioluminescence Resonance Energy Transfer (BRET) and Bimolecular Fluorescence Complementation 
(BiFC) Assays 
HEK-293T cells (American Type Culture Collection, ATCC, Mannassas, VA, USA) were 
transfected with a constant amount of cDNA for A2ARluc (0.2 µg) (intramural production, see 
[17,18,26,28]) and increasing amounts of cDNA for A2ARYFP (0.1 to 0.5 µg) (intramural production, 
see [17,18,26,28]); 48 h after transfection cells were adjusted to 20 µg of protein using a Bradford assay 
kit (Bio-Rad, Munich, Germany) using bovine serum albumin for standardization. To quantify 
protein-YFP expression, fluorescence was read in a Mithras LB 940 multimode microplate reader 
(Berthold Technologies, Bad Wilbad, Germany) which allows the integration of the signals detected 
in the short-wavelength filter at 485 nm and the long-wavelength filter at 530 nm. For BRET 
measurements, readings were collected 1 min after addition of 5 µM coelenterazine h (Molecular 
Probes, Eugene, OR). To quantify protein-Rluc expression, luminescence readings were done 10 min 
after 5 µM coelenterazine H addition. Net BRET is defined as [(long-wavelength emission)/(short-
wavelength emission)]–Cf, where Cf corresponds to [(long-wavelength emission)/(short-wavelength 
emission)] for the donor construct expressed alone in the same experiment. BRET is expressed as milli 
BRET, mBU (net BRET× 1,000) units. Data fitting with GraphPad Prism (San Diego, CA, USA) gave a 
saturation curve (Figure 2A) confirming that A2AR homodimers were formed under our experimental 
conditions. 
To address homodimer disruption, bimolecular fluorescence complementation assays were 
performed using HEK-293T cells transfected with equal amounts of cDNAs (0.75 µg cDNA each) for 
A2A-cYFP and A2A-nYFP fusion proteins (intramural production, see [17,18,26,28]). In the absence of 
peptides, molecular complementation took place and YFP was reconstituted by homodimer 
formation (Figure 2B); accordingly, YFP fluorescence was readily detectable. Fluorescence was 
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recorded in a Fluostar Optima fluorimeter (BMG Labtechnologies, Offenburg, Germany). 
Alternatively, cells were then treated with 0.4 µM of either of the four (1−4) peptides 4 h prior to the 
complementation assay, performed in supplemented Dulbecco’s modified Eagle’s medium (DMEM) 
medium. Values of fluorescence obtained in the absence or presence of peptides are given as mean ± 
standard error of the mean (SEM) of 16 independent experiments in duplicates. In all cases, one-way 
ANOVA followed by Bonferroni multiple comparison post hoc test were used for statistics analysis 
(*** p < 0.001; versus control. & p < 0.05 (Figure 2B). 
3.5. Cyclic Adenylic Acid(cAMP) Determination 
HEK-293T cell growth medium was replaced by serum-starved DMEM medium 2 h prior to the 
experiment. Next, cells were detached, suspended in growing medium containing 50 µM zardaverine 
and plated in 384-well microplates (2,500 cells/well), pretreated (15 min) with vehicle and stimulated 
with the receptor agonist (CGS21680, 15 min) before adding 0.5 µM forskolin or vehicle. Readings 
were performed after 1h incubation at 25 °C. Homogeneous time-resolved fluorescence energy 
transfer (HTRF) measures were performed using the Lance Ultra cAMP kit (PerkinElmer, Waltham, 
MA, USA). Fluorescence at 665 nm was analyzed on a PHERAstar Flagship microplate reader 
equipped with an HTRF optical module (BMG Lab technologies, Offenburg, Germany). 
4. Conclusions 
As of today, the best tools to decipher the physiological role of GPCR oligomers are peptides 
that disrupt the quaternary structure and allow exploration of the consequences of heteromer-related 
loss of function. The disrupting peptides are optimally delivered as chimeric constructs where a TM 
segment interfering with oligomerization is fused with a cell-penetrating sequence. In the present 
work, we show that the efficacy of linear peptide constructs of this type can be significantly improved 
by cyclization of their CPP segment. Thus, our TM5-interfering peptide 2 was able to disrupt A2AR 
homodimer formation to a larger extent than the fully linear version 1. The effect is clearly specific, 
as neither cyclic nor linear peptides containing the TM7 sequence, which does not lie within the dimer 
interface, were effective. A further attractive asset of the cyclic CPP strategy used here is that not only 
it makes the N- or C-termini of the CPP moiety impervious to proteases, but the alternating L- and D-
amino acid pattern used to favor cyclization confers additional resistance of 2 to proteolysis, as shown 
by the remarkable stability (ca. 80% unaltered after 24 h) to trypsin, unmatched by the linear version. 
In conclusion, we believe our TM5-interfering peptide 2 provides proof-of-principle for the 
design of optimized peptide-based disruptors of GCPR functionality, opening new perspectives for 
in vivo studies on the differential expression of functional A2AR homodimers in the brain and their 
implications in central nervous system (CNS) disease. 
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